Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

Password

Forgot your password?

Select specialty

First name

Last name

Choose Password

Playback speed

10 seconds

By National Jewish Health FEATURING Rebecca Keith

434 views

June 23, 2022

Please join Dr. Rebecca Keith pulmonologist at National Jewish Health and is an Associate Professor ...
read more ↘ in the Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, and Interstitial Lung Disease Program discussing the article “Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2022 May 15. doi: 10.1056/NEJMoa2201737. Epub ahead of print. PMID: 35569036” Here is the link to the journal article https://www.nationaljewish.org/education/pro-ed/live-events/national-jewish-health-journal-clubs/pdfs/njh-ild-june-article-summary.aspx
↖ read less

Comments 0